Financhill
Sell
44

NONOF Quote, Financials, Valuation and Earnings

Last price:
$87.40
Seasonality move :
4.97%
Day range:
$86.13 - $88.76
52-week range:
$77.95 - $149.55
Dividend yield:
1.66%
P/E ratio:
26.62x
P/S ratio:
9.26x
P/B ratio:
19.38x
Volume:
12.9K
Avg. volume:
96.2K
1-year change:
-26.73%
Market cap:
$388B
Revenue:
$42.1B
EPS (TTM):
$3.28

Analysts' Opinion

  • Consensus Rating
    No consensus rating exists at this time due to lack of analyst coverage.
  • Price Target Upside
    No price target exists because of limited analyst coverage.
  • Price Target Downside
    Similarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.

Fair Value

  • According to the consensus of 0 analysts, Novo Nordisk AS has 8.92% upside to fair value with a price target of -- per share.

NONOF vs. S&P 500

  • Over the past 5 trading days, Novo Nordisk AS has overperformed the S&P 500 by 12.2% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Novo Nordisk AS does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Novo Nordisk AS has grown year-over-year revenues for 18 quarters straight. In the most recent quarter Novo Nordisk AS reported revenues of $12.2B.

Earnings Growth

  • Novo Nordisk AS has grown year-over-year earnings for 10 quarters straight. In the most recent quarter Novo Nordisk AS reported earnings per share of $0.91.
Enterprise value:
397.7B
EV / Invested capital:
--
Price / LTM sales:
9.26x
EV / EBIT:
20.91x
EV / Revenue:
9.45x
PEG ratio (5yr expected):
1.24x
EV / Free cash flow:
39.35x
Price / Operating cash flow:
38.59x
Enterprise value / EBITDA:
18.91x
Gross Profit (TTM):
$35.6B
Return On Assets:
27.39%
Net Income Margin (TTM):
34.81%
Return On Equity:
86.85%
Return On Invested Capital:
60.28%
Operating Margin:
42.88%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Income Statement
Revenue $25B $33.7B $42.1B $9.5B $12.2B
Gross Profit $21B $28.5B $35.6B $8.1B $10.4B
Operating Income $10.6B $14.9B $18.6B $3.9B $5.2B
EBITDA $10.9B $16.8B $21B $4.1B $5B
Diluted EPS $1.73 $2.70 $3.28 $0.71 $0.91
Period Ending 2020-12-31 2021-12-31 2022-12-31 2023-12-31 2024-12-31
Balance Sheet
Current Assets $10.9B $13B $15.6B $20.7B $22.4B
Total Assets $24B $29.6B $34.7B $46.7B $65B
Current Liabilities $11.6B $15.1B $17.4B $25.2B $30.3B
Total Liabilities $13.5B $18.8B $22.7B $30.9B $45B
Total Equity $10.5B $10.8B $12B $15.8B $20B
Total Debt $1.1B $3.4B $3.1B $3.2B $13.4B
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Cash Flow Statement
Cash Flow Operations $11.2B $15.8B $17.6B $1.3B $1.5B
Cash From Investing -$3.5B -$6.4B -$18.7B -$2.1B -$13.1B
Cash From Financing -$7.3B -$9.2B $1.3B -$1.4B $5.4B
Free Cash Flow $9.1B $10.2B $10.1B -$1.1B -$786.4M
NONOF
Sector
Market Cap
$388B
$43.6M
Price % of 52-Week High
58.44%
47.61%
Dividend Yield
1.66%
0%
Shareholder Yield
1.95%
-0.67%
1-Year Price Total Return
-26.73%
-34.6%
Beta (5-Year)
0.509
0.747
Dividend yield:
1.66%
Annualized payout:
$1.45
Payout ratio:
43.71%
Growth streak:
4 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Buy
Level $82.26
200-day SMA
Sell
Level $117.52
Bollinger Bands (100)
Sell
Level 86.07 - 113.91
Chaikin Money Flow
Buy
Level 1M
20-day SMA
Buy
Level $83.91
Relative Strength Index (RSI14)
Buy
Level 55.26
ADX Line
Buy
Level 13.71
Williams %R
Neutral
Level -35.8635
50-day SMA
Sell
Level $88.56
MACD (12, 26)
Sell
Level -1.21
25-day Aroon Oscillator
Buy
Level 4
On Balance Volume
Neutral
Level 2.1M

Financial Scores

Buy
Altman Z-Score (Annual)
Level (6.9761)
Buy
CA Score (Annual)
Level (0.5179)
Buy
Beneish M-Score (Annual)
Level (-2.48)
--
Momentum Score
Level (--)
Buy
Ohlson Score
Level (-1.1119)
Buy
Piotroski F Score (Annual)
Level (5)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (9)

Revenue Forecast

Earnings per Share Forecast

Company Profile

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Stock Forecast FAQ

In the current month, NONOF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NONOF average analyst price target in the past 3 months is --.

  • Where Will Novo Nordisk AS Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Novo Nordisk AS share price will rise to -- per share over the next 12 months.

  • What Do Analysts Say About Novo Nordisk AS?

    Analysts are divided on their view about Novo Nordisk AS share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Novo Nordisk AS is a Sell and believe this share price will drop from its current level to --.

  • What Is Novo Nordisk AS's Price Target?

    The price target for Novo Nordisk AS over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is NONOF A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Novo Nordisk AS is a --. 0 of 0 analysts rate the stock a -- at this time.

  • How Can I Buy Shares Of NONOF?

    You can purchase shares of Novo Nordisk AS via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Novo Nordisk AS shares.

  • What Is The Novo Nordisk AS Share Price Today?

    Novo Nordisk AS was last trading at $87.40 per share. This represents the most recent stock quote for Novo Nordisk AS. Yesterday, Novo Nordisk AS closed at $87.40 per share.

  • How To Buy Novo Nordisk AS Stock Online?

    In order to purchase Novo Nordisk AS stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will AMD Beat the S&P 500?
Will AMD Beat the S&P 500?

High-performance and adaptive computing leader Advanced Micro Devices (NASDAQ:AMD) is…

Why Did Walmart Stock Fall?
Why Did Walmart Stock Fall?

Walmart (NYSE:WMT) tumbled in spite of strong Q4 results that…

Is Cadence Stock a Buy, Sell or Hold?
Is Cadence Stock a Buy, Sell or Hold?

Cadence Design Systems (NASDAQ:CDNS) has seen its stock move sharply…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 40x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Sell
48
Is MSFT Stock a Buy?

Market Cap: $3T
P/E Ratio: 35x

Alerts

Sell
2
GLOB alert for Feb 22

Globant SA [GLOB] is down 27.81% over the past day.

Sell
42
CELH alert for Feb 22

Celsius Holdings [CELH] is up 27.77% over the past day.

Buy
60
HIMS alert for Feb 22

Hims & Hers Health [HIMS] is down 25.64% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock